PRAX Reiterated by BTIG -- Price Target Maintained at $843.00
BTIG analyst Kambiz Yazdi has reiterated a 'Buy' rating for Praxis Precision Medicine (PRAX), maintaining a price target of $843.00. Despite this positive analyst outlook, GuruFocus indicates that PRAX is significantly overvalued by 923.4% and has a low GF Score™ of 40/100, raising concerns for potential investors due to the disparity between its current price and intrinsic value. The company's financial strength is rated highly, but profitability and valuation rank low.
Praxis (PRAX) CEO acquires 126 ESPP shares as compensation
Praxis Precision Medicines CEO Marcio Souza acquired 126 shares of Common Stock at $167.943 per share on May 14, 2026, through the company's Employee Stock Purchase Plan (ESPP). This compensation-related transaction, exempt under SEC Rules 16b-3(d) and 16b-3(c), increased his direct holdings to 77,016 shares, with an additional 2,600 shares held indirectly by his spouse. The filing clarifies that this was a routine plan purchase, not an open-market transaction.
Praxis (NASDAQ: PRAX) COO adds shares through Employee Stock Purchase Plan
Praxis Precision Medicines' Chief Operating Officer, Megan Sniecinski, acquired 89 shares of the company's common stock through an Employee Stock Purchase Plan at a price of $167.943 per share. Following this transaction, Sniecinski directly holds 28,664 common shares. This acquisition is reported as a routine, compensation-related event rather than an open-market purchase, exempt under SEC Rules 16b-3(d) and 16b-3(c).
[Form 4] Praxis Precision Medicines, Inc. Insider Trading Activity
Praxis Precision Medicines, Inc.'s Chief Financial Officer, Timothy Edwin Kelly, recently acquired 121 shares of common stock through an employee stock purchase plan at $167.943 per share. This transaction, which occurred on May 14, 2026, increased his direct holdings to 31,167 common shares. The acquisition was made under the company’s Employee Stock Purchase Plan and is considered exempt under SEC Rule 16b-3.
Praxis (NASDAQ: PRAX) counsel adds 78 ESPP shares, holds 26,010.667
Alex Nemiroff, General Counsel and Secretary of Praxis Precision Medicines (NASDAQ: PRAX), acquired 78 shares of company stock through an Employee Stock Purchase Plan (ESPP) at a price of $167.943 per share. This transaction, which is exempt under Rule 16b-3(d) and Rule 16b-3(c), increases his direct holdings to 26,010.667 shares. The article details the transaction, relevant SEC rules, and Nemiroff's updated total share ownership.
(PRAX) Volatility Zones as Tactical Triggers
This article, published on Stock Traders Daily, analyzes Praxis Precision Medicines Inc. (NASDAQ: PRAX) using AI models to identify volatility zones as tactical triggers. It details three trading strategies: Position Trading, Momentum Breakout, and Risk Hedging, tailored for different risk profiles and holding periods, alongside a multi-timeframe signal analysis. The analysis suggests a near-term strong sentiment potentially leading to a long-term positive bias for PRAX.
Needham Reiterates Praxis Precision Medicines (PRAX) Buy Recommendation
Needham has reiterated its Buy recommendation for Praxis Precision Medicines (PRAX). This indicates a continued positive outlook from the firm regarding the company's stock performance and future prospects.
Needham Reiterates Praxis Precision Medicines (PRAX) Buy Recommendation
Needham has reiterated its Buy recommendation for Praxis Precision Medicines (PRAX). The firm's analyst maintained a price target of $105.00 for the company, indicating continued confidence in its stock performance.
Point72 entities and Cohen report 0.2% stake in Praxis (PRAX)
Point72 entities and Steven A. Cohen have reported a 0.2% beneficial ownership stake in Praxis Precision Medicines Inc. (PRAX), amounting to 65,933 shares as of March 31, 2026. This disclosure was made via an amended Schedule 13G/A filing, indicating shared voting and dispositive power among several Point72-related entities. The filing clarifies the organizational structure of ownership, with Point72 Asset Management and Point72 Capital Advisors exercising investment power over shares held by affiliated LLCs, rather than direct ownership.
Praxis Precision Medicines stock (US74006W1036): Biotech innovator in CNS disorders
Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing precision therapies for central nervous system (CNS) disorders, including epilepsy and movement disorders. The company, trading on Nasdaq under PRAX, is advancing several pipeline assets through clinical trials, with key programs in Phase 2/3 and topline data expected soon. Praxis aims to address unmet needs in CNS conditions through a proprietary platform and relies on milestone payments and partnerships for future revenue, currently supported by $147 million in cash reserves as of Q4 2025.
Praxis Precision Medicines stock hits 52-week high at $358.01
Praxis Precision Medicines Inc. (PRAX) stock has reached a 52-week high at $358.01, marking an 838.98% increase over the past year despite a high beta of 2.78 and current unprofitability. The company reported better-than-expected Q1 2026 earnings per share of -$3.2 and Jefferies raised its price target to $550, citing promising catalysts in its neurology pipeline for 2026 and 2027. Investors can find detailed valuation and growth prospects in the comprehensive Pro Research Report.
Praxis (PRAX) widens Q1 2026 loss while advancing four late-stage CNS drugs
Praxis Precision Medicines reported a wider net loss of $92.6 million in Q1 2026, compared to $69.3 million a year earlier, due to increased spending on late-stage neurology programs. Despite the loss, the company has a strong cash position of $1.4 billion, projected to fund operations into 2028. Key advancements include FDA acceptance of NDAs for ulixacaltamide and relutrigine with upcoming PDUFA dates, and positive clinical data for elsunersen, with further pivotal trial readouts expected in 2026.
Praxis Precision Medicines stock hits 52-week high at $358.01 By Investing.com
Praxis Precision Medicines Inc. reached a 52-week high of $358.01, marking an 838.98% increase over the past year. Despite its current unprofitability and an InvestingPro assessment suggesting overvaluation, the company's Q1 2026 EPS of -$3.2 beat analyst expectations, and Jefferies raised its price target to $550, citing upcoming neurology pipeline catalysts.
Wedbush Maintained an Underperform Rating on Praxis Precision Medicines, Inc. (PRAX)
Wedbush maintained an "Underperform" rating on Praxis Precision Medicines, Inc., despite increasing its price target from $130 to $166, citing concerns over ulixacaltamide filing and valuation. The company recently announced FDA acceptance of NDAs for ulixacaltamide and relutrigine, with PDUFA dates in 2027 and 2026, respectively. Praxis ended the quarter with $1.4 billion in cash, extending its operational runway into 2028, and expects further clinical readouts in 2026.
Wedbush Maintained an Underperform Rating on Praxis Precision Medicines, Inc. (PRAX)
Wedbush maintained an "Underperform" rating on Praxis Precision Medicines, Inc. (PRAX), despite raising its price target from $130 to $166. The firm flagged concerns regarding the ulixacaltamide filing and valuation. Praxis recently announced FDA acceptance of NDAs for ulixacaltamide and relutrigine, with PDUFA dates in 2027 and 2026, respectively, and reported $1.4 billion in cash by March 2026, extending its runway into 2028.
10 Best Biotech Stocks to Invest In According to Billionaire Steve Cohen
This article highlights Praxis Precision Medicines, Inc. (NASDAQ: PRAX) as one of the best biotech stocks favored by billionaire Steve Cohen's Point72 Asset Management. It discusses recent analyst ratings, FDA acceptance of NDAs for ulixacaltamide and relutrigine with upcoming PDUFA dates, and the company's financial status including cash reserves and R&D spending. Praxis Precision Medicines is a clinical-stage biopharmaceutical company focusing on two proprietary platforms.
10 Best Biotech Stocks to Invest In According to Billionaire Steve Cohen
This article, part of a larger list, focuses on Praxis Precision Medicines, Inc. (NASDAQ:PRAX) as a key biotech stock favored by billionaire Steve Cohen's Point72 Asset Management. It details the company's recent FDA acceptances for ulixacaltamide and relutrigine, strong cash reserves, and upcoming clinical readouts. Despite an "Underperform" rating from Wedbush, the company shows significant pipeline progress and financial stability.
LifeSci Capital Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $795
LifeSci Capital has reiterated its Buy rating for Praxis Precision Medicines (PRAX.US), maintaining a target price of $795. This indicates a continued positive outlook from the firm regarding the company's stock performance and valuation. The article does not provide further details on the rationale behind the rating.
Praxis Precision Medicines Q1 Earnings Call Highlights
Praxis Precision Medicines is preparing for two potential U.S. product launches and advancing several late-stage clinical programs, as highlighted in its Q1 earnings call. The company is ramping up commercial efforts for ulixacaltamide and Relutrigine, with PDUFA dates set for January 29 next year and September 27. Praxis expects significant sales potential from its late-stage portfolio and anticipates key clinical trial results later this year and early next year.
A Quick Look at Today's Ratings for Praxis Precision Medicines(PRAX.US), With a Forecast Between $166 to $1,245
This article provides an overview of recent analyst ratings for Praxis Precision Medicines (PRAX.US), highlighting a predicted stock price range of $166 to $1,245. It includes specific analyst recommendations, price targets, and a breakdown of their performance, offering a quick glance at market sentiment and potential future stock movement.
Number of shareholders of Praxis Precision Medicines, Inc. – NASDAQ:PRAX
This article provides details about Praxis Precision Medicines, Inc. (NASDAQ: PRAX), specifically focusing on the number of its shareholders. It appears to be a financial data page from TradingView, presenting basic company information and market status. The key information is the "Number of shareholders" listed with a period, value, and change metrics.
A Quick Look at Today's Ratings for Praxis Precision Medicines(PRAX.US), With a Forecast Between $441 to $1,245
This article provides a detailed look at the current analyst ratings for Praxis Precision Medicines (PRAX.US). It highlights the range of price target forecasts, which analysts have set between $441 and $1,245. The article offers a quick overview of what financial experts think about the company's stock performance and future prospects.
Praxis Precision Medicines Q1 2026: Loss Narrows 12.1% to -$3.20/Share
Praxis Precision Medicines (NASDAQ: PRAX) reported a Q1 2026 loss of $3.20 per share, which beat analyst expectations of -$3.64 by 12.1%, with a net loss of $92.6M. Despite the narrowing loss compared to Q1 2025, the company's shares declined 2.0%, possibly due to profit-taking or broader sector weakness. Investors are focused on clinical data readouts and the company's capital runway for its drug development programs.
Jefferies raises Praxis Precision Medicines stock price target on pipeline catalysts
Jefferies has increased its price target for Praxis Precision Medicines (NASDAQ:PRAX) to $550 from $525, maintaining a Buy rating due to anticipated catalysts in the company's neurology pipeline in 2026 and 2027. Key programs like Vormatrigine, Relutrigine, and Ulixacaltamide are expected to yield significant market opportunities exceeding $750 million, $600 million, and $3 billion respectively. Despite the stock's volatile price movements, it has seen exceptional returns over the past year, and the company recently reported better-than-expected Q1 2026 earnings per share.
Q1 2026 Praxis Precision Medicines Inc Earnings Call Transcript
This document is a transcript of the Q1 2026 earnings call for Praxis Precision Medicines Inc. It includes introductory remarks from an unidentified company representative from LifeSci Advisors, welcoming participants and providing a disclaimer about forward-looking statements. The transcript indicates that the full content of the earnings call is restricted to subscribers.
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results
Praxis Precision Medicines has announced FDA acceptance for NDAs of ulixacaltamide for Essential Tremor and relutrigine for SCN2A and SCN8A DEEs, with PDUFA target action dates in early 2027 and late 2026, respectively. The company also reported positive Phase 1/2 study results for elsunersen in SCN2A-DEE, showing a 77% placebo-adjusted seizure reduction. Praxis is well-capitalized with $1.4 billion in cash and investments as of Q1 2026, maintaining its runway into 2028, and anticipates several key clinical readouts later this year.
Earnings call transcript: Praxis Precision beats Q1 2026 EPS forecasts
Praxis Precision Medicines exceeded Q1 2026 EPS forecasts, reporting -$3.2 against an expected -$3.6, driven by a strengthened cash position of $1.4 billion and progress in its product pipeline. The company is preparing for the commercial launches of ulixacaltamide and relutrigine in early 2027 and late 2026, respectively, and is advancing other clinical programs like the EMERALD study for relutrigine and the POWER1 study for vormatrigine. Despite a daily stock price decline, the company's long-term outlook is optimistic, supported by strategic investments and strong interest from healthcare professionals and patients.
Praxis (PRAX) secures $1.4B cash as epilepsy and tremor NDAs advance
Praxis Precision Medicines reported a net loss of $92.6 million for the first quarter of 2026 but ended the period with $1.4 billion in cash, boosted by a $621.2 million equity offering. The company is advancing two New Drug Applications (NDAs) with the FDA: ulixacaltamide for essential tremor (PDUFA date January 29, 2027) and relutrigine for SCN2A/SCN8A developmental and epileptic encephalopathies (priority review with PDUFA date September 27, 2026), positioning them for potential commercialization. This financial stability is expected to fund operations into 2028, supporting their CNS pipeline.
Press Release: Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results
This article announces that Praxis Precision Medicines has provided a corporate update and reported its first-quarter 2026 financial results. It briefly mentions that Unity Software reported its fourth-quarter earnings, with revenue increasing 35% year-over-year to $609 million, although the company reported a quarterly loss per share. The full details of Praxis Precision Medicines' update and results are stated to be behind a login wall.
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results
Praxis Precision Medicines announced the FDA acceptance of NDAs for ulixacaltamide in Essential Tremor and relutrigine in SCN2A and SCN8A DEEs, positioning them for two U.S. launches. The company reported positive EMBRAVE Part A study results for elsunersen, showing a 77% placebo-adjusted reduction in monthly seizures in SCN2A-DEE patients. Praxis ended Q1 2026 with $1.4 billion in cash, extending its operational runway into 2028, and anticipates several key clinical trial readouts this year.
Praxis Precision Medicines (Nasdaq:PRAX) - Stock Analysis
This extensive analysis of Praxis Precision Medicines (PRAX) details its financial health, future growth prospects, and a comprehensive overview of its drug pipeline. Key highlights include recent FDA acceptances for ulixacaltamide in essential tremor and relutrigine in pediatric epilepsy, analyst price targets, and a history of significant stock performance and volatility. The company is developing therapies for central nervous system disorders and has multiple late-stage candidates with upcoming regulatory milestones.
LifeSci Capital Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Raises Target Price to $795
LifeSci Capital has reiterated its 'Buy' rating for Praxis Precision Medicines (PRAX.US) and increased its price target to $795. This action indicates a strong bullish outlook on the company's future performance by the investment firm.
FMR LLC holds 7.7% of Praxis Precision Medicines (PRAX) — 2.16M shares
FMR LLC has filed a Schedule 13G/A, reporting beneficial ownership of 2,156,343.22 shares, or 7.7%, of Praxis Precision Medicines (PRAX) common stock as of March 31, 2026. These shares are held on behalf of others, with no single other person holding more than 5%. The filing indicates FMR LLC has sole voting power over 2,152,365.75 shares and sole dispositive power over 2,156,343.22 shares.
Praxis gives 21 new employees stock awards tied to hiring
Praxis Precision Medicines, Inc. (Nasdaq: PRAX) announced that it granted restricted stock units covering 5,420 shares to 21 new non-executive employees on May 1, 2026. These inducement grants were made under the company's 2024 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The restricted stock units will vest in four equal annual installments, contingent upon the employees' continued employment.
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Praxis Precision Medicines, Inc. announced that its Compensation Committee granted restricted stock unit awards covering 5,420 shares of common stock to twenty-one new non-executive employees. These grants were made on May 1, 2026, under the 2024 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The awards will vest in four equal annual installments, contingent upon continued employment.
Praxis Precision Medicines Inc expected to post a loss of $3.57 a share - Earnings Preview
Praxis Precision Medicines Inc (PRAX) is projected to report a loss of $3.57 per share in its upcoming earnings. The company's earnings preview indicates this financial performance. The report is based on information from Refinitiv.
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Praxis Precision Medicines, Inc. announced that its Compensation Committee granted restricted stock unit awards totaling 5,420 shares of common stock to twenty-one new non-executive employees. These grants were made under the company's 2024 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4), to incentivize their employment. The awards vest in four equal annual installments, contingent on continued employment.
Praxis maps out two investor events in May, starting with Q1 results
Praxis Precision Medicines (NASDAQ: PRAX) announced it will report its first quarter 2026 financial results and provide a corporate update on Thursday, May 7, 2026, before market open, followed by a conference call and webcast at 8:30 am ET. Additionally, the company will present at the Bank of America Securities Health Care Conference on Tuesday, May 12, 2026, at 7:20 pm EDT, with a live webcast and replay available. These events are part of Praxis's ongoing investor engagement strategy to contextualize recent advancements in its CNS precision neuroscience pipeline.
Wolfe Research initiates coverage of Praxis Precision Medicines (PRAX) with outperform recommendation
Wolfe Research has initiated coverage of Praxis Precision Medicines (PRAX) with an "Outperform" recommendation. This analyst rating suggests that the firm believes PRAX's stock will perform better than the overall market or its sector. This news is relevant for investors tracking pharmaceutical companies and new analyst ratings.
Wolfe Research initiates coverage of Praxis Precision Medicines (PRAX) with outperform recommendation
Wolfe Research has initiated coverage of Praxis Precision Medicines (PRAX) with an outperform recommendation. This indicates a positive outlook from the research firm regarding the company's stock performance.
Praxis (NASDAQ: PRAX) details 2026 virtual meeting, director slate and Say-on-Pay
Praxis Precision Medicines, Inc. is holding its 2026 virtual annual meeting on June 10, 2026, where stockholders will vote on the election of three Class III directors, the ratification of Ernst & Young LLP as auditor, and an advisory Say-on-Pay resolution regarding executive compensation. The company reported a 283% one-year return for stockholders in 2025, driven by significant clinical, regulatory, and capital-raising milestones. Praxis has also evolved its executive compensation program for 2026 to include performance-based restricted stock units (PSUs) to further align executive incentives with company performance and long-term value creation.
Vanguard (NASDAQ: PRAX) reports 1.42M shares, 5.09% stake in Praxis
Vanguard Capital Management has disclosed a significant passive investment in Praxis Precision Medicines Inc (NASDAQ: PRAX), reporting beneficial ownership of 1,419,323 shares, which constitutes a 5.09% stake. The Schedule 13G filing indicates Vanguard has sole dispositive power over all these shares and sole voting power over 197,379 shares, with the filing signed by Ashley Grim, Head of Global Fund Administration, on April 30, 2026. This disclosure provides transparency regarding institutional ownership and potential influence on the company's governance and economic outcomes.
Pictet Asset Management Holding SA Makes New $71.09 Million Investment in Praxis Precision Medicines, Inc. $PRAX
Pictet Asset Management Holding SA has made a significant new investment of $71.09 million in Praxis Precision Medicines, Inc. during the fourth quarter, acquiring 240,588 shares. This purchase gives Pictet Asset Management approximately 0.96% ownership, contributing to the 67.84% institutional ownership of the company. Analysts maintain a "Buy" rating for Praxis with an average target price of $590.78, despite the company currently operating at a loss.
Moody Aldrich Partners LLC Buys New Position in Praxis Precision Medicines, Inc. $PRAX
Moody Aldrich Partners LLC has acquired a new position in Praxis Precision Medicines (NASDAQ:PRAX), purchasing 41,731 shares valued at approximately $12.3 million in Q4, making it their largest holding. Despite Praxis missing Q4 EPS estimates, Wall Street analysts have a consensus "Buy" rating for PRAX with a target price of $590.78, with some firms setting targets as high as $1,245. The company specializes in neurological and psychiatric precision therapies and 67.84% of its stock is owned by institutional investors.
Praxis Precision Medicines stock drops 2.74% as positive Phase 3 Essential Tremor data shared at AANAM
Praxis Precision Medicines (PRAX) stock dropped 2.74% despite the company preparing to present positive Phase 3 Essential Tremor data and other CNS pipeline data at the AANAM event. The stock experienced a 6.64% pullback this week with heightened volatility, but technical analysis suggests that medium- and long-term trends remain bullish. Analysts predict a price fluctuation between $308 and $345 next week, with a high probability of a bounce due to strong bullish signals.
Optimism Surrounds Praxis Precision Medicines (PRAX) Amid Potential FDA Approval for Ulixacaltamide
Praxis Precision Medicines (PRAX) is seen as a strong biotech stock, with analysts giving it a predominantly bullish rating and a median 1-year target price of $625.31. Raymond James assigned a Strong Buy rating with an $815 target, emphasizing the undervalued potential of ulixacaltamide's expected FDA approval in early 2027. The company focuses on therapies for central nervous system disorders using proprietary platforms.
How Investors May Respond To Praxis (PRAX) Securing Dual FDA Reviews For Key Neurology Drug Candidates
Praxis Precision Medicines (PRAX) has achieved two significant FDA milestones: Priority Review for relutrigine in pediatric epilepsy, with a PDUFA date in September 2026, and acceptance of the NDA for ulixacaltamide in essential tremor, with a PDUFA date in January 2027. These developments suggest Praxis is evolving into a multi-asset regulatory pipeline company. Despite ongoing losses and dilution risk, these catalysts are expected to sharpen the focus on successful approvals and potentially lead to a substantial upside in its stock price.
10 Best Biotech Stocks with Highest Upside Potential
This article identifies Praxis Precision Medicines Inc. (NASDAQ: PRAX) as one of the top biotech stocks with high upside potential. Analysts have a strongly bullish sentiment towards the company, with a median 1-year target price suggesting over 81% upside. Raymond James even projects a 136% upside, citing the undervalued likelihood of FDA approval for ulixacaltamide in early 2027, which is expected to be a significant commercial catalyst.
Universal Beteiligungs und Servicegesellschaft mbH Takes Position in Praxis Precision Medicines, Inc. $PRAX
Universal Beteiligungs und Servicegesellschaft mbH has acquired a new stake of 37,377 shares, valued at approximately $11.02 million, in Praxis Precision Medicines (NASDAQ:PRAX), representing 0.15% of the company. Other institutional investors have also adjusted their holdings in PRAX. Analysts currently have a consensus "Buy" rating on PRAX with a target price of $590.78, despite the company missing its recent quarterly earnings estimates.
Praxis Precision Medicines Prepares for Major FDA Decisions in 2026
Praxis Precision Medicines (NASDAQ:PRAX) is nearing major regulatory milestones with two FDA decisions anticipated in late 2026 and early 2027. The company's lead compounds, relutrigine for pediatric epilepsy and ulixacaltamide for essential tremor, have received priority review and NDA acceptance respectively. With a robust cash reserve of $1.5 billion, Praxis aims to finance its own commercial launches and avoid shareholder dilution.
